Shasun Pharmaceuticals today said it has received the US health regulator’s nod to market pain relief drug Carisoprodol in the US market.
In a BSE filing, Shasun Pharmaceuticals said, “It has received approval from the United States Food and Drug Administration (US FDA) for Carisoprodol tablets.”
The approval is for the 250 mg and 350 mg strengths.
Shasun Pharma said Carisoprodol tablets of 250 mg and 350 mg have sales of approximately $38 million.
“While the 350 mg has a few generic players, Shasun expects to be the first marketed generic player in the $16 million Carisoprodol tablets of 250 mg opportunity,” it added.
Shasun Pharmaceuticals said the product will be manufactured at its Puducherry plant and distributed through a partner. It’s expected to be launched shortly.
The stock of Shasun Pharmaceuticals was trading at Rs 404.60 on BSE, up 1.67 per cent, from its previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.